Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
复制标题
DOI：
10.1200/jco.2007.12.4008
复制
发表时间：
2008-01-10
影响因子：
45.3
通讯作者：
Tannock, Ian F.
中科院分区：
文献类型：
--
作者：
Berthold, Dominik R.;Pond, Gregory R.;Tannock, Ian F.
TAX 327研究比较了多西他赛每3周给药一次（D3）、多西他赛每周给药一次（D1）和米托蒽醌（M），每种药物均联合泼尼松（P）治疗1,006例转移性耐药前列腺癌（HRPC）患者。最初的分析是在2003年8月进行的，当时发生了557例死亡，与MP相比，D3 P的生存率和疼痛，前列腺特异性抗原（PSA）和生活质量的反应率显着更好。在这里，我们报告了一个更新的分析survival.MethodsInvestigators被要求提供死亡或最后一次随访的日期为所有参与者谁是活着的2003.ResultsBy 2007年3月，获得310个额外的死亡数据（总= 867死亡）。与MP相比，D3 P的生存获益随着随访时间的延长而持续存在（P = .004）。中位生存期为19.2个月（95% CI，17.5 - 21.3个月），D3 P组，17.8个月（95% CI，16.2 - 19.2个月），D1 P组为16.3个月与MP组（13.5%）相比，D3 P和D1 P组（分别为18.6%和16.6%）中生存≥ 3年的患者更多（95% CI，14.3至17.9个月）。治疗组之间的生存率相似的趋势，男性大于和小于65岁，对于那些有和没有疼痛的基线，和那些基线PSA大于和小于中位数值115 ng/mL.ConclusionThe目前的分析证实，转移性HRPC的男性的生存期显着长于D3 P治疗后，比MP。在患者亚组中观察到一致的结果。
PurposeThe TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with MP. Here, we report an updated analysis of survival.MethodsInvestigators were asked to provide the date of death or last follow-up for all participants who were alive in August 2003.ResultsBy March 2007, data on 310 additional deaths were obtained (total = 867 deaths). The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004). Median survival time was 19.2 months (95% CI, 17.5 to 21.3 months) in the D3P arm, 17.8 months (95% CI, 16.2 to 19.2 months) in the D1P arm, and 16.3 months (95% CI, 14.3 to 17.9 months) in the MP arm. More patients survived >= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%). Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.ConclusionThe present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP. Consistent results are observed across subgroups of patients.